Utility of PET/CT in patients with stage I-III melanoma

被引：9
作者：
Aviles Izquierdo, J. A. [1 ]
Molina Lopez, I. [1 ]
Sobrini Morillo, P. [2 ]
Marquez Rodas, I. [3 ,4 ]
Mercader Cidoncha, E. [5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Serv Dermatol, Calle Dr Esquerdo 46, Madrid 28007, Spain
[2] Univ Complutense Madrid, Fac Med, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Serv Oncol Med, Madrid, Spain
[4] Ciberonc, Madrid, Spain
[5] Hosp Gen Univ Gregorio Maranon, Serv Cirugia Gen, Madrid, Spain
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2020年 / 22卷 / 08期
关键词：
Melanoma; Diagnosis; Staging; PET; CT; Sentinel lymph node biopsy; Complete lymph node dissection; Skin metastases; F-18-FDG PET/CT; TOMOGRAPHY; CT;
D O I：
10.1007/s12094-019-02252-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose To study the utility of positron emission tomography with computerized tomography (PET/CT) in patients with a stage I-III melanoma. Patients and methods PET/CT findings from all patients with a stage I-III melanoma attended at our hospital from September 2011 to November 2015 were reviewed. Results Data from 83 patients with a stage I-III melanoma, 39 patients with a positive sentinel lymph node biopsy (SLNB) and 35 patients with locoregional recurrences were analyzed. Sensitivity of PET/CT in clinical stage I-III patients was 5%, with a 14% of false positives. In patients with a positive SLNB, PET/CT previous to complete lymph node dissection had a 23% of false negatives. In patients with clinical locoregional recurrences, PET/CT findings revealed asymptomatic visceral distant metastasis in 25.7%. Conclusions PET/CT has a significant rate of false positive and negative results in patients with a stage I-III melanoma. Utility in patients with nodal locoregional recurrences seems higher than in patients with skin metastases.
引用
收藏
页码：1414 / 1417
页数：4
相关论文
共 15 条
  • [1] [Anonymous], 2019, NCCN CLIN PRACTICE G
  • [2] Positron Emission Tomography/Computed Tomography in Melanoma
    Bourgeois, Austin C.
    Chang, Ted T.
    Fish, Lindsay M.
    Bradley, Yong C.
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2013, 51 (05) : 865 - +
  • [3] Sentinel lymph node biopsy versus PET-CT in AJCC stages I and II of melanoma
    Chessa, M. A.
    Dika, E.
    Patrizi, A.
    Fanti, P. A.
    Piraccini, B. M.
    Veronesi, G.
    Diodato, S.
    De Vivo, S.
    Fanti, S.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : E54 - E55
  • [4] Diagnostic accuracy of 18F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma
    Gellen, E.
    Santha, O.
    Janka, E.
    Juhasz, I.
    Peter, Z.
    Erdei, I.
    Lukacs, R.
    Fedinecz, N.
    Galuska, L.
    Remenyik, E.
    Emri, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (10) : 1938 - 1944
  • [5] Sentinel Lymph Node Excision and PET-CT in the Initial Stage of Malignant Melanoma: A Retrospective Analysis of 61 Patients with Malignant Melanoma in American Joint Committee on Cancer Stages I and II
    Klode, Joachim
    Dissemond, Joachim
    Grabbe, Stephan
    Hillen, Uwe
    Poeppel, Thorsten
    Boeing, Carsten
    [J]. DERMATOLOGIC SURGERY, 2010, 36 (04) : 439 - 445
  • [6] Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy
    Kong, Benjamin Y.
    Menzies, Alexander M.
    Saunders, Catherine A. B.
    Liniker, Elizabeth
    Ramanujam, Sangeetha
    Guminski, Alex
    Kefford, Richard F.
    Long, Georgina V.
    Carlino, Matteo S.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (05) : 572 - 577
  • [7] Breslow thickness and 18F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established?
    Ortega-Candil, A.
    Rodriguez-Rey, C.
    Cano-Carrizal, R.
    Cala-Zuluaga, E.
    Gonzalez Larriba, J. L.
    Jimenez-Ballve, A.
    Fuentes-Ferrer, M. E.
    Cabrera-Martin, M. N.
    Perez-Castejon, M. J.
    Garcia Garcia-Esquinas, M.
    Lapena-Gutierrez, L.
    Carreras-Delgado, J. L.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (02): : 96 - 101
  • [8] 18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis
    Perng, Powell
    Marcus, Charles
    Subramaniam, Rathan M.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2015, 205 (02) : 259 - 269
  • [9] PET/Computed Tomography and Patient Outcomes in Melanoma
    Rohren, Eric M.
    [J]. PET CLINICS, 2015, 10 (02) : 243 - 254
  • [10] Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
    Sachpekidis, Christos
    Larribere, Lionel
    Pan, Leyun
    Haberkorn, Uwe
    Dimitrakopoulou-Strauss, Antonia
    Hassel, Jessica C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (03) : 386 - 396
12